Abstract:Introduction NCAPD3 (Non-SMC Condensin II Complex Subunit D3) is a regulatory subunit of the condensing-2 complex. Recent studies have shown that somatic mutations in genes encoding subunits of condensins associated with microcephaly, primary autosomal recessive and several cancers. NCAPD3 was highlighted as an outcome predictor in pancreatic ductal adenocarcinoma (PDAC) and a new biomarker for subtype-1 prostate cancer that improves prognostication. Yet, no literature has been reported regarding the expression and biological role of NCAPD3 in diffuse large B cell lymphoma (DLBCL). Hence, the aim of our study is to evaluate the functional significance and mechanism of NCAPD3 in DLBCL. Methods Peripheral blood mononuclear cells (PBMCs) were obtained from healthy volunteers with informed consents. Expression levels of NCAPD3 mRNA and protein in DLBCL cell lines and PBMCs were detected by quantitative RT-PCR and western blotting. Immunohistochemistry (IHC) was conducted to assess the expression of NCAPD3 on paraffin-embedded tissues from 70 de novo DLBCL patients (study group) and 35 reactive hyperplasia patients (control group) with informed contents. Microarray datasets GSE32918 and GSE83632 were obtained from Gene Expression Omnibus. Survival analysis, protein-protein interaction (PPI) and gene set enrichment analysis (GSEA) in gene expression profiles were performed. Lentivirus vectors either targeting NCAPD3 (shNCAPD3) or empty lentiviral vector (shControl) were stably transfected into DLBCL cells. Cell proliferation was analyzed by cell counting kit (CCK-8). The apoptosis and cell cycle assays were carried out by flow cytometry. p < 0.05 was considered statistically significant. Results Markedly increased expression of NCAPD3 was detected in DLBCL cell lines at mRNA and protein level compared to those in healthy volunteers' PBMCs (Fig. 1a-b). We also observed higher NCAPD3 expression levels in DLBCL tissues than in reactive hyperplasia upon IHC staining (Fig. 1c). Expression of NCAPD3 protein was revealed in significant positive correlation with advanced Ann Arbor stage (p=0.046) and IPI score (p=0.017, Fig. 1d). Bioinformatics analysis showed that high NCAPD3 expression in DLBCL was turned up to be correlate with shorter overall survival according to GSE32918 (p=0.013, Fig. 2a). PPI network and GSEA indicated that NCAPD3 was functional enriched in chromatin regulation, cell cycle, histone methylation, NF-κB signaling and Toll-like receptor signaling pathway (Fig. 2b-c). Relevant mechanism is now the focus of ongoing experiments. Lentivirus mediated loss-of-function assays were performed to further investigate the biological role of NCAPD3 in DLBCL. Effective knockdown (shNCAPD3) was confirmed by qRT-PCR and western blot (Fig. 3a-b). Stable expression of shNCAPD3 in DLBCL cells exhibited growth suppression, increased fast-onset apoptosis, and induced GO/G1 phase arrest when compared to the control group (Fig. 3c-e). Conclusion Our investigations identified for the first time the oncogenic role of NCAPD3 in DLBCL tumorigenesis by bioinformatics analysis and in vitro evaluation. Expression of NCAPD3 was upregulated, and associated with adverse outcome of DLBCL patients. NCAPD3 inhibition by RNAi exerted anti-tumor efficacy in inhibiting cell growth, promoting apoptosis and blocking cell cycle. This study suggests that Sirt6 could be a potential molecular target for the treatment of DLBCL. Further study on it is under way. Disclosures No relevant conflicts of interest to declare.

Over-expression of CLN3P, the Batten disease protein, inhibits PANDER-induced apoptosis in neuroblastoma cells: Further evidence that CLN3P has anti-apoptotic properties

The Batten Disease Gene CLN3 Confers Resistance to Endoplasmic Reticulum Stress Induced by Tunicamycin.

The CLN3 gene is a novel molecular target for cancer drug discovery

Loss of the lysosomal protein CLN3 modifies the lipid content of the nuclear envelope leading to DNA damage and activation of YAP1 pro-apoptotic signaling

Intracellular trafficking of CLN3, the protein underlying the childhood neurodegenerative disease, Batten disease.

CLN3 deficiency leads to neurological and metabolic perturbations during early development

NCAPD3 Regulates Tumor Growth and Predicts Prognosis in Diffuse Large B-Cell Lymphoma

Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses

Bioinformatics analysis of human natten disease-associated gene CLN3 and its mutation*

Persistent P21 Expression after Nutlin-3a Removal is Associated with Senescence-Like Arrest in 4n Cells

The Batten disease protein CLN3 is important for stress granules dynamics and translational activity

Structure-function studies of PANDER, an islet specific cytokine inducing cell death of insulin-secreting beta cells.

Membrane topology of CLN3, the protein underlying Batten disease.

Effects of overexpression of pancreatic derived factor (FAM3B) in isolated mouse islets and insulin-secreting TC3 cells

PCLAF Promotes Neuroblastoma G1/S Cell Cycle Progression Via the E2F1/PTTG1 Axis.

Pander-Induced Cell-Death Genetic Networks in Islets Reveal Central Role for Caspase-3 and Cyclin-Dependent Kinase Inhibitor 1a (P21)

Targeted disruption of pancreatic-derived factor (PANDER, FAM3B) impairs pancreatic beta-cell function.

Loss of the batten disease protein CLN3 leads to mis-trafficking of M6PR and defective autophagic-lysosomal reformation

Rare Deleterious PARD3 Variants in the Apkc-Binding Region Are Implicated in the Pathogenesis of Human Cranial Neural Tube Defects Via Disrupting Apical Tight Junction Formation.

Screening for calcium channel modulators in CLN3 siRNA knock down SH-SY5Y neuroblastoma cells reveals a significant decrease of intracellular calcium levels by selected L-type calcium channel blockers

CLN3 is required for the clearance of glycerophosphodiesters from lysosomes